-

Research Insights

The “Cryptococcosis: Pipeline Review, Developer Landscape and Competitive Insights, 2022-2035” report features an extensive study on the marketed, clinical and preclinical molecules available / being developed for the treatment of Cryptococcosis. This report provides an in-depth analysis of the product pipeline and developer companies, highlighting the current treatment practices, emerging drugs, and market share of the individual therapies. In addition to other elements, the stud

...read more

The “Uterine Serous Carcinoma: Pipeline Review, Developer Landscape and Competitive Insights, 2025-2035” report features an extensive study on the marketed, clinical and preclinical molecules available / being developed for the treatment of uterine serous carcinoma. This report provides an in-depth analysis of the product pipeline and developer companies, highlighting the current treatment practices, emerging drugs, and market share of the individual therapies. In addition to othe

...read more

The “Polycystic Ovarian Syndrome (PCOS): Pipeline Review, Developer Landscape and Competitive Insights, 2025-2035” report features an extensive study on the marketed, clinical and preclinical molecules available / being developed for the treatment of polycystic ovarian syndrome. This report provides an in-depth analysis of the product pipeline and developer companies, highlighting the current treatment practices, emerging drugs, and market share of the individual therapies. In add

...read more

The “Dravet Syndrome: Pipeline Review, Developer Landscape and Competitive Insights, 2025-2035” report features an extensive study on the marketed, clinical and preclinical molecules available / being developed for the treatment of Dravet syndrome. This report provides an in-depth analysis of the product pipeline and developer companies, highlighting the current treatment practices, emerging drugs, and market share of the individual therapies. In addition to other elements, the st

...read more

The “Pompe Disease: Pipeline Review, Developer Landscape and Competitive Insights, 2025-2035” report features an extensive study on the marketed, clinical and preclinical molecules available / being developed for the treatment of Pompe Disease. This report provides an in-depth analysis of the product pipeline and developer companies, highlighting the current treatment practices, emerging drugs, and market share of the individual therapies. In addition to other elements, the study

...read more

Infectious diseases are known to be one of the top 10 leading causes of deaths, worldwide.  In-fact, more than 40 million people are affected by various types of infectious diseases annually. An article published in The Lancet journal reported that COVID-19 alone caused death of over 18 million people in 2020. Further, it has been reported that human immunodeficiency virus (HIV) is anticipated to be the cause for 6.5 million deaths globally, by 2030. Over the past few years, a number of ant

...read more

Given the recent shift from the one-size-fits-all model to a more personalized mode of treatment, there has been a growing interest in identification and adoption of novel techniques. It is estimated that there are around 20,000 genes present in the human body, all of which interact with the nutrients in the food, either directly or indirectly. Since the introduction of a gene sequencing method by Frederick Sanger in 1977, the field of genomic data collection and analysis has evolved significant

...read more

The “Amnesia: Pipeline Review, Developer Landscape and Competitive Insights, 2022-2035” report features an extensive study on the marketed, clinical and preclinical molecules available / being developed for the treatment of Amnesia. This report provides an in-depth analysis of the product pipeline and developer companies, highlighting the current treatment practices, emerging drugs, and market share of the individual therapies. In addition to other elements, the study includes det

...read more

The “Graft versus Host Disease (GvHD): Pipeline Review, Developer Landscape and Competitive Insights, 2022-2035” report features an extensive study on the marketed, clinical and preclinical molecules available / being developed for the treatment of GvHD. This report provides an in-depth analysis of the product pipeline and developer companies, highlighting the current treatment practices, emerging drugs, and market share of the individual therapies. In addition to other elements,

...read more

Globally, cancer is one of the leading causes of death; in 2020, about 10 million cancer related deaths were reported. Further, according to a study published in American Cancer Society Journal, by 2040, the number of cancer cases is projected to reach over 28 million, indicating a cumulative growth of nearly 47%, since 2020. The continuous growth in the number of cancer patients imposes a huge burden, in terms of finances as well as resources, on  the overall healthcare system. In this con

...read more

Cell and gene therapy candidates have been demonstrated to have the potential to treat complex and rare diseases, including indications, for which no effective treatment is currently available. In this context, it is important to mention that, in case of cell therapy, human cells are transplanted to repair or replace the damaged cells / tissues, thereby, enabling their treatment through alteration or restoration of certain sets of cells. The cells may originate from the patient (autologous cells

...read more

RNA sequencing was first introduced by Fredrick Sanger in 1977, who used chain termination method, also known sanger sequencing method / first generation sequencing method. It is a rapid method that enables profiling of whole range of RNA expressed by the cell, with increased coverage and resolution. However, the sanger sequencing method costs higher as compared to other methods and has low detection power, which reduces its scalability. Over time, this domain has witnessed several technological

...read more

Over the last few decades, the development landscape of small molecule drugs has been significantly impacted by various biotechnology breakthroughs. Further, with the advent of novel technologies, biologics have made a significant impact in the pharmaceutical domain, delivering ground-breaking treatment for a myriad of disease indications, including immunological, oncological and rare disorders. In this context, it is worth highlighting those 14 biopharmaceutical products (including cell therapi

...read more

It is a well-known fact that almost 90% of the therapeutic interventions fail in clinical trials, resulting in significant economic losses to the pharmaceutical industry.  The lack of effective preclinical prediction of drug responses in humans is one of the various reasons for drug’s failure to get approved. Animal testing for preclinical evaluation of drugs sometimes fails to identify toxicity signs caused by a drug in humans. Moreover, these studies are quite expensive, time-consum

...read more

Cancer is known to be one of the leading causes of deaths, worldwide. In fact, as per the annual statistics reported by the American Cancer Society (ACS) indicate that, in 2022, around 1.9 million individuals are likely to be diagnosed with various types of cancer in the US. Further, it is estimated that, by the end of 2040, 27.5 million new cancer cases will be added to the global numbers, exerting tremendous physical, emotional and financial strain on affected individuals, their families, comm

...read more

Every year, the healthcare industry generates a massive amount of data. In fact, the healthcare data currently constitutes around 30% share of the global data volume. Further, it is estimated that, by 2025, the data generated via the healthcare sector will rise at an annualized growth rate of 36%. However, it is important to consider that the constant management of such enormous volumes of data is a tedious and challenging process. Specifically, management and handling of huge datasets in the he

...read more

The “Soft Tissue Sarcoma: Pipeline Review, Developer Landscape and Competitive Insights, 2022-2035” report features an extensive study on the marketed, clinical and preclinical molecules available / being developed for the treatment of soft tissue sarcoma. This report provides an in-depth analysis of the product pipeline and developer companies, highlighting the current treatment practices, emerging drugs, and market share of the individual therapies. In addition to other elements

...read more

The “Vitiligo: Pipeline Review, Developer Landscape and Competitive Insights, 2022-2035” report features an extensive study on the marketed, clinical and preclinical molecules available / being developed for the treatment of vitiligo. This report provides an in-depth analysis of the product pipeline and developer companies, highlighting the current treatment practices, emerging drugs, and market share of the individual therapies. In addition to other elements, the study includes d

...read more
  • We are your partners with no equity

  • We fit in your budget

  • We love what we do

  • Chance to prove ourselves

  • Best in class quality of work

  • Most trusted consulting partner in the industry